Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Published: Mar 18, 2011
SAN DIEGO, March 18, 2011 /PRNewswire/ -- Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The primary endpoint of the study is progression free survival.
Peter Szlosarek, M.D., Ph.D., of the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, is the lead investigator of the study. "It is with great anticipation that the ADAM trial has opened at Barts and other cancer centers in the U.K., including hospitals in Belfast, Cambridge, Hull, Manchester and Southampton," said Dr. Szlosarek. "We are pleased to be joining Polaris Group in exploring the potential benefits of ADI-PEG 20 in treatment of different cancers."
Malignant mesothelioma is a cancer of the lungs that frequently occurs in people who have been exposed to asbestos. The disease is usually diagnosed two to three decades after prolonged exposure and when it has generally spread beyond the stage for successful surgical treatment. The prognosis for patients with late stage malignant mesothelioma is poor with a median survival of less than one year.
Polaris Group scientists and colleagues have been investigating the metabolic enzyme argininosuccinate synthetase (ASS) and its presence or absence in relationship to growth of normal cells and tumor cells. ASS is required for the production of arginine, an amino acid needed for growth and replication of cells. Normal cells have normal levels of ASS and can produce sufficient arginine for their own growth and survival. However, many types of tumor cells cannot make their own arginine due to a deficiency in ASS and, therefore, must obtain it from external sources. ADI-PEG 20 depletes the external supply of arginine, causing these tumor cells to die.
The sensitivity of several ASS-deficient tumor cell lines to ADI-PEG 20 has been recently reported at the 2010 Annual Meeting of the American Association for Cancer Research. Previous studies supported by Cancer Research UK (CR-UK) and conducted by Dr. Szlosarek demonstrated that 63 percent of patients with malignant mesothelioma had low levels or no ASS in their tumor tissues. The study also demonstrated that viability of mesothelioma cell lines from these patients declined markedly when deprived of arginine if they were ASS-negative.
Robert Jackson, Ph.D., chairman of the CR-UK Discovery Committee, and a member of the Polaris Scientific Advisory Board, commented: "We are very excited to have started the study with ADI-PEG 20 in malignant mesothelioma. Dr. Szlosarek has been one of the leaders in researching and targeting ASS-deficient tumors with ADI-PEG 20. The initiation of this mesothelioma trial with ADI-PEG 20 is a good example of a CR-UK funded laboratory study forming the basis of a new experimental treatment. CR-UK is committed to such important translational research initiatives in cancer."
John Bomalaski, M.D., executive vice president, medical affairs, of Polaris Group, added, "We are very excited about the potential of using ADI-PEG 20 to treat multiple forms of cancer. We are already evaluating ADI-PEG 20 in a Phase 2 trial in small cell lung cancer, and we look forward to initiating additional trials in tumors with a high degree of ASS deficiency. Our belief is that ADI-PEG 20 will play a key role in the future as single agent therapy or in combination chemotherapy for several cancers that continue to evade effective treatment."
About Polaris Group
Polaris Group is a privately held multinational biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company's lead therapeutic, ADI-PEG 20, is advancing into a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris is also investigating ADI-PEG 20 as a treatment for other arginine-dependent cancers, such as prostate cancer, leukemia, lymphoma, sarcoma and pancreatic cancer. In addition to the ADI-PEG 20 project, Polaris is researching and developing other biotherapeutic agents and has a small molecule drug program that utilizes rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.
For additional information please visit www.polarispharma.com
SOURCE Polaris Group